Twist Bioscience Corp
Ticker: TWSTHealthcareBiological ProductsThe business
Twist Bioscience Corporation (NASDAQ: TWST) operates as a leading provider of synthetic DNA and related life sciences solutions, serving customers across research, development, and commercial applications globally. The company's website is www.twistbioscience.com.
The company has developed a disruptive DNA synthesis platform that industrializes the engineering of biology through proprietary silicon-chip-based technology. Rather than using traditional plate-based synthesis methods, Twist manufactures synthetic DNA by writing over one million oligonucleotide pieces directly onto silicon chips approximately the size of a large mobile phone, reducing chemical usage by an estimated 99.8% compared to conventional approaches. This core platform combines silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure, and an e-commerce platform to deliver high-quality, precise, and cost-effective DNA synthesis at significant manufacturing throughput.
Twist generates revenue through two primary product lines and a services offering. The synthetic biology segment includes synthetic genes, gene fragments, oligonucleotide pools, IgG proteins, and synthetic controls. The next-generation sequencing tools segment provides library preparation kits, exome kits, fixed and custom panels, and workflow solutions for diagnostic applications. The company also offers comprehensive biopharma services for antibody discovery, optimization, and development, including in vivo, in vitro, and in silico discovery platforms. In fiscal year 2025, the company reported revenue of $376.6 million, with healthcare representing $215.1 million, chemicals and materials $93.2 million, academic research $65.9 million, and food and agriculture $2.4 million.
The company serves more than 3,800 customers across academic institutions, biopharmaceutical companies, diagnostic firms, and industrial biotechnology organizations. As of September 30, 2025, Twist employed 979 people across its operations, including 412 in manufacturing and operations, 278 in sales and marketing, 198 in general and administrative functions, and 91 in research and development. The company operates manufacturing facilities in South San Francisco, California and Wilsonville, Oregon, and maintains a global commercial presence through direct sales personnel, e-commerce platforms, and commercial consultants in Europe and Asia.
- Sector
- Healthcare
- Industry
- Biological Products
- HQ
- SOUTH SAN FRANCISCO, CA
- FY end
- 09-30
- CIK
- 1581280
- SIC
- 2836
Ownership
Who holds Twist Bioscience Corp — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| ARK Innovation ETF ARKK · ARK ETF Trust | 3.05% | $197.72M |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.01% | $192.85M |
| iShares Russell 2000 ETF IWM · iShares Trust | 0.20% | $163.99M |
| State Street(R) SPDR(R) S&P(R) Biotech ETF XBI · SPDR SERIES TRUST | 1.41% | $151.14M |
| VANGUARD SMALL-CAP INDEX FUND VB · VANGUARD INDEX FUNDS | 0.07% | $139.63M |
Superinvestors in Twist Bioscience Corp
Share of each manager's reported 13F portfolio.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of Twist Bioscience Corp's financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free